Docoh
Loading...

NBIX Neurocrine Biosciences

Employees

Data from SEC filings
Employee count
CEO pay ratio
CEO Salary
Median Employee Salary

ESG framework mentions

In last year of SEC filings
Sustainability Accounting Standards Board (SASB)
No mentions
Global Reporting Initiative (GRI)
No mentions
Task Force on Climate-related Financial Disclosures (TCFD)
No mentions
UN Sustainable Development Goals (SDGs)
No mentions

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM
The 2021 Annual Meeting of Stockholders of the Company (the “Annual Meeting”) was held on May 19, 2021. As of the close of business on March 23, 2021, the record date for the Annual Meeting, there were 94,535,739 shares of common stock entitled to vote, of which there were 85,244,517 shares present at the Annual Meeting in person or by proxy. At the Annual Meeting, stockholders voted on three matters: (i) the election of three Class I Directors for a term of three years expiring at the 2024 Annual Meeting of Stockholders, (ii) an advisory vote on the compensation paid to the Company’s named executive officers, and (iii) the ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021. The voting results were as follows:

• Election of three Class I Directors for a term of three years expiring at the 2024 Annual Meeting of Stockholders.

William H. Rastetter, Ph.D.For70,689,819 Withheld9,590,937
George J. MorrowFor75,617,578 Withheld4,663,178
Leslie V. NorwalkFor63,595,461 Withheld16,685,295


There were 4,963,761 broker non-votes for this proposal.

The three nominees for Class I Director were elected. The Class II Directors, Richard F. Pops, Shalini Sharp and Stephen A. Sherwin, M.D., will continue in office until the 2022 Annual Meeting of Stockholders or until their earlier death, resignation or removal. The Class III Directors, Kevin C. Gorman, Ph.D., Gary A. Lyons and Johanna Mercier will continue in office until the 2023 Annual Meeting of Stockholders, or until their earlier death, resignation or removal.

• An advisory vote on the compensation paid to the Company’s named executive officers.

Shares Voted:For77,232,378Against2,952,915Abstain95,463
Percent of Voted:For96.20 %Against3.67 %


There were 4,963,761 broker non-votes for this proposal.

The compensation of the Company’s named executive officers, as disclosed in the Proxy Statement, was approved on an advisory basis.

•Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2021.



Shares Voted:For82,408,785Against2,768,444Abstain67,288
Percent of Voted:For96.67 %Against3.24 %


The appointment of Ernst & Young LLP was ratified.